Redoxis is a research institute located in Lund that specializes in preclinical drug development. The organization focuses on efficacy evaluation for models related to autoimmune diseases, providing a range of customized services tailored to meet the specific needs of its clients. Redoxis employs a portfolio of continuously updated disease models, ensuring that their research remains relevant and effective.
In addition to efficacy evaluation, Redoxis offers in vitro testing and analysis, as well as secondary analysis to provide comprehensive insights into drug development processes. The institute combines its academic research roots with practical applications, emphasizing personal collaboration with clients throughout various stages of preclinical research and evaluation. This approach allows Redoxis to deliver knowledge and competence that supports the advancement of drug development initiatives.